ADMELOG SOLOSTAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADMELOG SOLOSTAR (ADMELOG SOLOSTAR).
Insulin lispro, a rapid-acting insulin analog, lowers blood glucose by binding to and activating the insulin receptor, leading to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, fat) and suppression of hepatic glucose production.
| Metabolism | Insulin lispro is metabolized primarily by endocytosis and subsequent degradation via proteolytic enzymes, predominantly in the liver and kidneys. No significant CYP450 metabolism. |
| Excretion | Renal: 30-80% of dose excreted unchanged in urine; biliary/fecal: negligible. |
| Half-life | Terminal elimination half-life: 5-6 hours for insulin lispro; clinical context: reflects duration of glucose-lowering effect, allowing dosing before meals. |
| Protein binding | <10% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.26-0.38 L/kg; clinical meaning: limited distribution to interstitial fluid. |
| Bioavailability | Subcutaneous: approximately 55-77% of administered dose reaches systemic circulation. |
| Onset of Action | Subcutaneous: 10-30 minutes. |
| Duration of Action | Subcutaneous: 3-5 hours; clinical notes: rapid onset and short duration suitable for meal-time coverage. |
Subcutaneous injection starting dose 0.2-0.4 units/kg/day divided into 1-2 injections, or 0.1-0.2 units/kg/meal for prandial coverage; typical total daily dose 0.5-1.0 units/kg.
| Dosage form | SOLUTION |
| Renal impairment | GFR <30 mL/min: reduce dose by 25-50% due to decreased insulin clearance; monitor glucose closely. |
| Liver impairment | Child-Pugh Class B or C: reduce dose by 20-40% due to impaired gluconeogenesis and altered insulin metabolism. |
| Pediatric use | Weight-based: 0.5-1.0 units/kg/day total, divided; for prandial: 0.1-0.2 units/kg/meal. Adjust based on blood glucose. |
| Geriatric use | Lower initial doses (0.2-0.4 units/kg/day) to reduce hypoglycemia risk; titrate cautiously. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ADMELOG SOLOSTAR (ADMELOG SOLOSTAR).
| Breastfeeding | Insulin lispro is excreted in breast milk in negligible amounts; M/P ratio not established. It is considered compatible with breastfeeding, but monitoring of infant glucose levels is recommended due to potential for neonatal hypoglycemia. No adverse effects on the nursing infant have been reported. |
| Teratogenic Risk | Insulin lispro does not cross the placenta in significant amounts. No increased risk of major congenital malformations has been observed with insulin lispro use during pregnancy. There is a potential risk of maternal hypoglycemia and fetal harm if glycemic control is inadequate, especially in the first trimester for organogenesis and in the second and third trimesters for fetal growth and development. |
■ FDA Black Box Warning
Never share an ADMELOG SOLOSTAR prefilled pen between patients, even if the needle is changed. Sharing poses a risk for transmission of bloodborne pathogens.
| Serious Effects |
["Hypersensitivity to insulin lispro or any of its excipients.","During episodes of hypoglycemia."]
| Precautions | ["Hypoglycemia is the most common adverse reaction; may be life-threatening if severe.","Changes in insulin regimen (e.g., strength, type, or timing) require close medical supervision and dose adjustment.","Hypokalemia may occur if not managed appropriately.","Monitor renal and hepatic function; dose adjustments may be required in impairment.","Thiazolidinediones (TZDs) used in combination with insulin may increase risk of heart failure.","Rotate injection sites to reduce risk of lipodystrophy or localized cutaneous amyloidosis."] |
| Food/Dietary | No significant food interactions. However, timing of insulin should be aligned with meals. Avoid alcohol, which can increase risk of hypoglycemia. Consistent carbohydrate intake is recommended for glucose control. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels frequently during pregnancy (preprandial, postprandial, and bedtime). Assess HbA1c every 1-2 months. Perform fetal surveillance with ultrasound for growth and anatomy, and nonstress testing or biophysical profiles in the third trimester. Monitor for maternal hypoglycemia and diabetic ketoacidosis. |
| Fertility Effects | Insulin lispro has no known direct adverse effects on fertility. Proper glycemic control is essential for maintaining normal reproductive function in diabetic patients. Uncontrolled diabetes may impair fertility due to hormonal imbalances. |
| Clinical Pearls | Admelog (insulin lispro) is a rapid-acting insulin analog with onset of action ~15 minutes, peak at 30-90 minutes, and duration 2-4 hours. For Solostar pens, prime before each use by dialing 2 units and pointing needle upward to expel air. Rotate injection sites (abdomen, thigh, deltoid) to prevent lipodystrophy. Use immediately after drawing from vial; do not mix with other insulins unless specifically directed. Monitor for hypoglycemia, especially in patients with renal impairment or elderly. |
| Patient Advice | Inject Admelog within 15 minutes before or immediately after a meal. · Do not reuse needles; dispose of sharps in puncture-proof container. · Store unopened pens in refrigerator; opened pens can be kept at room temperature (below 86°F) for up to 28 days. · Never share pens or needles even if needle is changed. · Signs of hypoglycemia: shakiness, sweating, confusion, fast heartbeat; treat with fast-acting sugar (glucose tablets, juice). · Rotate injection sites to avoid lumps or skin thickening. · Check blood glucose before each dose and as directed. · Do not use if solution appears cloudy, colored, or has particles. |